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Abstract  Lipoprotein  (a)  [Lp(a)]  is  a modified LDL par-
ticle with an additional apolipoprotein [apo(a)] protein co-
valently attached by a thioester bond. Multiple isoforms of 
apo(a) exist that are genetically determined by differences 
in the number of Kringle-IV type-2 repeats encoded by the 
LPA gene. Elevated plasma Lp(a) is an independent risk 
factor for cardiovascular disease.
The phenotypic diversity of familial Lp(a) hyperlip-
idemia [Lp(a)-HLP] and familial hypercholesterolemia 
[FH],  as  defined  risks with  genetic  background,  and  their 
frequent co-incidence with additional cardiovascular risk 
factors require a critical revision of the current diagnostic 
and therapeutic recommendations established for isolated 
familial Lp(a)-HLP or FH in combination with elevated 
Lp(a) levels.
Lp(a) assays still suffer from poor standardization, com-
parability and particle variation. Further evaluation of the 
current biomarkers and establishment of novel comorbid-
ity biomarkers are necessary for extended risk assessment 
of cardiovascular disease in FH or Lp(a)-HLP and to bet-
ter understand the pathophysiology and to improve patient 
stratification of the Lp(a) syndrome complex.
Lp(a) promotes vascular remodeling, increased lesion 
progression and intima media thickening through induc-
tion of M1-macrophages, antiangiogenic effects (e.g. vasa 
vasorum) with secretion of the antiangiogenic chemokine 
CXCL10 (IP10) and CXCR3 mediated activation of Th1- 
and NK-cells.
In addition inhibition of serine proteases causing dis-
turbances  of  thrombosis/  hemostasis/  fibrinolysis,  TGFb-
activation and acute phase response (e.g. CRP, anti-PL 
antibodies) are major features of Lp(a) pathology. Anti-PL 
antibodies (EO6 epitope) also bind to oxidized Lp(a).
Lipoprotein apheresis is used to reduce circulating lipo-
proteins in patients with severe FH and/or Lp(a)-HLP, par-
ticularly with multiple cardiovascular risks who are intol-
erant or insufficiently responsive to lipid-lowering drugs.
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Zusammenfassung  Lipoprotein (a) [Lp(a)] ist ein modifi-
zierter LDL-Partikel assoziiert mit Apolipoprotein [Apo(a)], 
as an den LDL-Partikel durch eine kovalente Thioesterbin-
dung gebunden ist. Es sind mehrere genetisch determinier-
te Apo(a)-Isoformen bekannt, die sich durch die Anzahl 
der Typ-2 Kringle-IV Domänen unterscheiden.
Eine erhöhte Lp(a) Plasmakonzentration ist ein unab-
hängiger Risikofaktor für kardiovaskuläre Erkrankungen.
Aufgrund der phänotypischen Heterogenität der fa-
miliären Lp(a)-Hyperlipoproteinämie [Lp(a)-HLP] und 
der familiären Hypercholesterinämie [FH], als genetisch-
definierte  Risiken,  sowie  deren  häufige  Koinzidenz  mit 
weiteren kardiovaskulären Risikofaktoren, müssen die ak-
tuellen diagnostischen und therapeutischen Empfehlungen 
nochmals überprüft werden, die für die isolierte Lp(a)-HLP 
oder FH ohne erhöhtes Lp(a), bzw. deren Kombination mit 
erhöhten Lp(a)-Spiegeln etabliert wurden.
Die derzeit am Markt befindlichen Lp(a)-Bestimmungs-
methoden sind ungenügend standardisiert, nicht exakt ver-
gleichbar und berücksichtigen nicht die Variabilität der 
Partikelgröße. Die aktuellen Biomarker erfordern eine 
Ergänzung und Validierung durch neue Komorbiditäts-
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Marker, die die Pathogenese der kardiovaskulären Risiko-
faktoren bei FH oder Lp(a)-HLP präziser beschreiben und 
eine  bessere  Stratifizierung  von  Patienten mit  Lp(a)-Syn-
dromen ermöglichen.
Lp(a) fördert die vaskuläre Remodellierung, die zu ei-
ner Progression der atherosklerotischen Läsion und Verdi-
ckung der vaskulären Intima durch Induktion von M1-Ma-
krophagen führen, sowie damit assoziierte antiangiogene-
tische Prozesse (z. B. Vasa vasorum) wie die Sekretion des 
anti-angiogenischen Chemokins CXCL10 (IP10) und des 
Th1- und NK-Zellen aktivierenden Chemokins CXCR3.
Darüber hinaus hemmt Lp(a) verschiedene Serinpro-
teasen, die Störungen im Thrombose/Hämostase/Fibri-
nolyse-System verursachen können. Weitere pathogene 
Eigenschaften  der  Lp(a)  sind  die  TGFb-Aktivierung  und 
die Induktion einer Akute-Phase-Response Reaktion (z. B. 
CRP-Erhöhung, Synthese von Anti-PL-Antikörpern). Anti-
PL-Antikörper (EO6 Epitope) binden bevorzugt an oxi-
dierte Lp(a).
Die therapeutische Lipoprotein-Apherese wird bei 
schwerwiegenden FH- und/oder Lp(a)-HPL-Fällen zur Re-
duktion der zirkulierenden Lipoproteinkonzentration einge-
setzt. Insbesondere Patienten mit multiplen Risikofaktoren, 
mit Medikamentenunverträglichkeit von Lipidsenkern oder 
mit unzureichender Lipidsenkung sollten mit der Lipida-
pherese behandelt werden.
Schlüsselwörter Lipoprotein(a) · Kardiovaskuläres 
Risiko · Pathophysiologie · Biomarker
Introduction
Atherosclerotic cardiovascular disease (CVD) is one of the 
major factors for morbidity and mortality in Western coun-
tries. Established risk factors for CVD, include elevated 
plasma concentration of lipoprotein(a) (Lp(a)), high plasma 
concentration of low density lipoprotein (LDL), low plasma 
concentration of high density lipoprotein (HDL), hyperten-
sion, diabetes, obesity, metabolic syndrome and smoking 
among others [1–3 and references therein]. Since the ath-
erogenic process leading to CVD begins in childhood and 
is progressive throughout the life span [2], screening for 
risk factors, appropriate patient stratification and therapeu-
tic management are essential. Lp(a)-hyperlipidemia (Lp(a)-
HLP) has been reported as an independent risk factor for 
CVD [4–6 and references therein]. Lp(a)-HLP occurs either 
alone, or in combination with other genetic backgrounds for 
hyperlipidemia and CVD risk, such as familial hypercholes-
terolemia (FH) or apolipoprotein E4-allele, therefore early 
recognition of diverse co-morbidities is essentially required 
[3]. However, despite of considerable efforts, the precise 
pathophysiological mechanisms, how Lp(a) contributes to 
atherogenesis, are not fully elucidated.
Lipoprotein(a) hyperlipidemia (Lp(a)-HLP)
Lipoprotein(a)  [Lp(a)],  first  described  by  Berg  in  1963 
[7], is composed of apolipoprotein (a) (apo(a)), covalently 
attached to apolipoprotein B-100 (apoB-100) by a disul-
fide bond on kringle-IV type-9 (KIV9) in close proximity to 
the LDL receptor binding site of apoB-100 [8]. The apo(a) 
gene (LPA) is a major determinant of the plasma concentra-
tion of Lp(a), and several genetic LPA-variants have been 
described, including variations in the kringle region-coding 
repeats, which account for the size polymorphism of apo(a), 
diverse single nucleotide polymorphisms (SNPs) and other 
variants in the promoter of LPA [9–11]. There is an inverse 
relationship between the number of kringle repeats of apo(a) 
and the concentration of Lp(a) in plasma (reviewed in 5). 
The plasma levels of Lp(a) show significant diversity in eth-
nical groups (e.g. African-Americans have higher plasma 
Lp(a) concentrations than Caucasians), and in individuals 
carrying apo(a) even of the same size polymorphism [10, 
11], but the underlying mechanisms have yet to be identi-
fied. The latter issue implies the possibility of the presence 
of additional factors for CVD risk of Lp(a).
Measurement of Lp(a) in plasma
Quantitative determination of Lp(a) in human plasma (or 
serum) is currently a standard approach of clinical laborato-
ries. In contrast to first generation immunoassays, recogniz-
ing kringle-IV type-2 (KIV2), current diagnostic antibodies 
bind to KIV9, and this binding site is more stable than KIV2, 
even in frozen samples [12]. Taking into account that the 
molecular weight of apo(a), depending on the genetic poly-
morphisms of apo(a), varies between 275 and 800 kDa in 
different individuals [5], plasma levels of Lp(a) expressed 
in mg/L or mmol/L may lead to confusion. At present, there 
is no commercial Lp(a) assay that is completely insensitive 
to the variability in Lp(a) particle mass, and Lp(a) mass 
refers to the entire mass of the whole particle, including lip-
ids, proteins and carbohydrates [13]. In their recent paper 
McConnell and co-workers claim for novel mass-insen-
sitive Lp(a) assays, since lipoprotein “particle number” 
seems to be superior to component-based metrics for CVD 
risk prediction [13]. In a very recent work the simultane-
ous quantitation and size characterization of apo(a) by ultra-
performance liquid chromatography/mass spectrometry was 
reported [14]. The latter may be an initial step for develop-
ment of mass-insensitive Lp(a) assays in the future.
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was able to inhibit the recognition and uptake of oxidized 
phospholipids and apoptotic cells by macrophage scavenger 
receptors, and reduce the progression of CVD in an athero-
sclerosis-susceptible mouse model [reviewed in 24]. The 
innate immune system recognizes OSEs as danger-associ-
ated molecular patterns (DAMPs), and uses innate pattern 
recognition receptors and soluble factors for their clearance 
[25 and references therein]. The E06 immunoreactivity of 
apo(a), indicating pro-inflammatory oxidized phospholipids 
accessible to DAMPs, was found to be strongly influenced 
by KIV10, which may explain the atherogenic potential of 
Lp(a) [26]. In addition, Lp(a) and oxidized LDL (oxLDL) 
both bind monocyte chemoattractant protein-1 (MCP-1/
CCL2), a major chemokine in induction and progression 
of vascular inflammation, and oxidized phospholipids were 
shown to be major determinants for MCP-1 binding [27]. 
Based on the critical role of oxidized phospholipids and 
OSEs in Lp(a)-associated atherogenesis, development of 
atheroprotective vaccines recognizing and masking OSEs 
may be beneficial to reduce CVD risk.
The  levels  of  oxidized  phospholipids  are modified  by 
the activity of lipoprotein-associated phospholipase A2 
(Lp-PLA2, former platelet activating factor acetylhydro-
lase, PAFAH), which converts oxidized phospholipids to 
oxidized fatty acids and lysophosphatidylcholine (lysoPC) 
[24, 28]. Both lipid species have been shown to be pro-
inflammatory and pro-atherogenic  in vitro. Stronger asso-
ciation of Lp-PLA2 was found with Lp(a) as compared to 
LDL [28].
In a recent study release of phosphatidylcholine-contain-
ing oxidized phospholipids and oxidized cholesteryl esters, 
such as oxidized derivatives from cholesteryl linoleate and 
cholesteryl arachidonate, was demonstrated downstream 
from obstructive plaques in human, and these bioactive lip-
ids were captured during percutaneous interventions [29]. 
This study clearly shows the presence of critical pro-inflam-
matory and pro-atherogenic lipids in the local microcircula-
tion in human arterial tissue.
Taken together, Lp(a) exerts its pro-atherogenic role via 
multiple mechanisms, and the precise compositional analy-
sis of Lp(a) particles contributes to a sophisticated evalua-
tion of Lp(a)-associated CVD risk.
Lp(a)-lowering therapy
Currently it is unclear if lowering Lp(a) levels will also 
reduce the risk of CVD, since the first specific Lp(a) decreas-
ing compound(s) have recently been developed and clinical 
outcome data have not yet been published [6].
Several previous pharmacological approaches have 
shown Lp(a)-lowering effects (e.g. nicotinic acid, oestro-
gen, eprotirome, antisense apoB-100, inhibitors of choles-
Lipoprotein(a) in atherogenesis
The kringle domains of apo(a) show high degree of homol-
ogy to the kringle-IV and kringle-V of plasminogen, the 
zymogen  for  the  fibrinolytic  serine  protease  plasmin,  and 
the atherogenic potential of Lp(a) is partially attributed 
to this structural homology [reviewed in 15]. The kringle 
structure of Lp(a) and plasminogen differs in one single 
amino acid (R560S), and it protects apo(a) from enzymatic 
cleavage by plasminogen activators, such as tissue-type 
plasminogen activator (t-PA) and urokinase plasminogen 
activators (u-PA) [9, 15]. In addition to this molecular 
mimicry of Lp(a) to plasminogen, there are further mecha-
nisms contributing to the role of Lp(a) in atherogenesis and 
development of CVD: (1) Lp(a) is able to bind to the tissue 
factor pathway inhibitor (TFPI), which is responsible for 
the prothrombotic properties of Lp(a) [16]. (2) Lp(a) can 
dock on certain lipoprotein receptors, including LDL recep-
tor (LDLR), LDLR-related protein(s) and very low density 
lipoprotein (VLDL) receptor, leading to Lp(a) internaliza-
tion, although to a lesser extent than the natural ligands of 
these receptors [17]. (3) Lp(a) can be entrapped by matri-
cellular proteins (e.g. laminin, thrombospondin, tetranectin, 
fibrinogen/fibrin,  glycosaminoglycans,  fibronectin),  lead-
ing to retention of Lp(a) and recruitment of monocytes in 
atherosclerotic lesions [15, 18]. (4) Lp(a) leads to endothe-
lial barrier dysfunction through dysregulated myosin light 
chains via a Rho/Rho-kinase mediated signalling, and in 
this process a strong lysine-binding site in kringle-IV type-
10 (KIV10) of apo(a) plays an essential role [19]. (5) Lp(a) 
modulates  inflammatory  responses  and  abolishes  recruit-
ment of neutrophils [20]. (6) Lp(a) promotes the differen-
tiation  of  pro-inflammatory,  M1-type  macrophages,  that 
secrete CXCL10 (IP10) chemokine leading to activation of 
T-helper-1 (Th1) lymphocytes and natural killer (NK) cells 
[21–23]. The chemokine CXCL10 is increasingly regarded 
as a potent inhibitor of angiogenesis, that may affect vasa 
vasorum angiogenesis. Thus Lp(a) may perpetuate vascu-
lar remodelling by blocking myoepithelial organization of 
newly formed vascular tubes. The importance of CXCL10 
in vascular disease progression is further supported by the 
expanding literature.
In recent years Witztum and co-workers have demon-
strated in consecutive papers that a substantial portion of 
pro-inflammatory  and  pro-atherogenic  oxidized  phospho-
lipids, produced in response to reactive oxygen species 
(ROS), is present on apo(a) and Lp(a) [24 and references 
therein]. By  using  epitope-specific monoclonal  antibodies 
(particularly E06, but also others), recognizing oxidized but 
not  native  phospholipids  (i.e.  oxidation-specific  epitopes, 
OSEs), they have found plasma levels of oxidized phospho-
lipids correlating with concentrations of Lp(a) in plasma, 
apo(a) size polymorphism and CVD [24]. The E06 antibody 
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teryl ester transfer protein (CETP), monoclonal antibodies 
against apo(a) or proprotein convertase subtilisin/kexin 
type-9 (PCSK9)), but the decrease of plasma Lp(a)-levels 
in Lp(a)-HLP are/were  insufficient without major  adverse 
effects [reviewed in 6].
Prevention and/or adequate treatment of additional CVD 
risks such as smoking, obesity, hypertension, diabetes, 
alcohol consumption, although they are important interven-
tions, have no major impact in the management of Lp(a)-
HLP [1, 2].
The long-time use of Lp(a) apheresis in combination with 
maximal tolerated doses of lipid-lowering drugs reduced the 
plasma concentrations of Lp(a) by over 70 %, parallel with a 
decrease of the mean annual rate of major adverse coronary 
events, as a measure of outcome, in a recent longitudinal, 
multicenter, cohort study [30].
The recommendations of the HEART-UK Working 
Group  indicates  that  patients  with  progressive  CVD,  and 
with plasma concentrations of Lp(a) above 60 mg/dL, and 
plasma LDL cholesterol above 3.2 mmol/L (despite of max-
imal lipid-lowering drug therapy) should be considered for 
LDL apheresis [31]. Although LDL apheresis is able to pro-
vide reduced plasma concentrations of Lp(a), based on the 
structural similarities of LDL and Lp(a) particles, patients 
with isolated Lp(a)-HLP should rather be treated by Lp(a) 
apheresis [reviewed in 32].
The lack of clear guidance for the indication of Lp(a) 
apheresis treatment requires further efforts, but most apher-
esis centers work currently with the criteria of (i) 60 mg/
dL Lp(a) in plasma as cut-off, and (ii) history of advanced 
and/or progressive CVD, and alternatively (iii) presence of 
additional risk factors for CVD that accelerate the course of 
disease [3].
Further studies are required, however, (a) to optimize 
management in order to reduce CVD risk associated with 
Lp(a)-HLP, and (b) to evaluate what other intermediate and/
or high risk groups may benefit from Lp(a) screening [33].
Conclusion
Despite of emerging data from clinical and experimental 
studies our current knowledge about the impact of Lp(a)-
HLP in development of atherogenic CVD is still insuf-
ficient. A critical  reappraisal of  the current diagnostic and 
screening criteria as well as therapeutic recommendations is 
required. Further evaluation of recent, and establishment of 
novel biomarkers are necessary for appropriate risk assess-
ment of CVD in Lp(a)-HLP. Novel mass-insensitive Lp(a) 
assays should be developed for precise laboratory screen-
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